Evidence map›Paper›PMID 35366247›Full record

ArticlePathophysiology : the official journal of the International Society for Pathophysiology2021

The Usefulness of Rare Blood Group Systems in the Risk Determination for Severe COVID-19.

Theocharis G Konstantinidis, Valeria Iliadi, Georges Martinis, Maria Panopoulou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathophysiology : the official journal of the International Society for Pathophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Theocharis G KonstantinidisBlood Transfusion Center, University General Hospital of Alexandroupolis Dragana Campus, 68100 Alexandroupolis, Greece.ORCID 0000-0003-4296-3414
Valeria IliadiIzhevsk State Medical Academy, Kommunarov Street 281, 426034 Izhevsk, Russia.
Georges MartinisBlood Transfusion Center, University General Hospital of Alexandroupolis Dragana Campus, 68100 Alexandroupolis, Greece.
Maria PanopoulouLaboratory of Microbiology, Democritus University of Thrace, University General Hospital of Alexandroupolis Dragana Campus, 68100 Alexandroupolis, Greece.
Democritus University of Thrace · GRIzhevsk State Medical Academy · RUUniversity Hospital of Alexandroupolis · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The newly identified human coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on a detailed analysis of clinical manifestation. It was reported that blood type O individuals were less likely to become infected by SARS-CoV, while blood type A individuals have an increased risk of severe illness. The Forssman antigen, or Forssman glycolipid synthase (FS), was first described in 1911 by John Frederick Forssman. Blood type A/B glycosyltransferases (AT/BTs) and Forssman glycolipid synthase (FS) are encoded by the evolutionarily related ABO (A/B alleles) and

Indexed as

blood typeCOVID-19Forssman antigen

Identifiers

PMID35366247
PMCPMC8830445
OpenAlexW3210424400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.